Discontinuous drug combination therapy in autoimmune ocular disorders
暂无分享,去创建一个
[1] Douglas A Jabs,et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. , 2005, American journal of ophthalmology.
[2] A. Okada. Noninfectious uveitis: a scarcity of randomized clinical trials. , 2005, Archives of ophthalmology.
[3] J. Forrester,et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. , 2005, Archives of ophthalmology.
[4] S. Lightman,et al. Clinical outcome of chronic immunosuppression in patients with non‐infectious uveitis , 2005, Clinical & experimental ophthalmology.
[5] D. Jabs,et al. IMMUNOSUPPRESSION FOR POSTERIOR UVEITIS , 2005, Retina.
[6] Y. Shoenfeld,et al. Intraocular inflammation in autoimmune diseases. , 2004, Seminars in arthritis and rheumatism.
[7] J. Dunn. Review of immunosuppressive drug therapy in uveitis , 2004, Current opinion in ophthalmology.
[8] L. Rostaing,et al. COMPARISON OF INDUCTION THERAPY BASED ON CONTINUOUS VS. DISCONTINUOUS ADMINISTRATION OF ANTI-THYMOCYTE GLOBULINS IN RENAL-TRANSPLANT PATIENTS: EFFICACY AND LONG-TERM SAFETY , 2004 .
[9] L. Rostaing,et al. Comparison of induction based on continuous vs discontinuous administration of antithymocyte globulins in renal transplant patients: efficacy and long-term safety. , 2004, Transplantation Proceedings.
[10] C. Foster,et al. Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety. , 2004, Ophthalmology.
[11] B. Laganà,et al. Autoimmune disorders: a concept of treatment based on mechanisms of disease , 2003, Springer Seminars in Immunopathology.
[12] E. Woodle,et al. Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on cd3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients , 2002, Transplantation.
[13] Justine R. Smith,et al. Management of uveitis: a rheumatologic perspective. , 2002, Arthritis and rheumatism.
[14] N. Waheed,et al. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. , 2001, Ophthalmology.
[15] R. V. Van Gelder,et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. , 2000, American journal of ophthalmology.
[16] J. Forrester,et al. Cyclosporin A therapy in refractory non-infectious childhood uveitis , 1998, The British journal of ophthalmology.
[17] C. Chan,et al. Immunopathology of uveitis , 1985, The British journal of ophthalmology.
[18] Q. Nguyen,et al. Cicatricial Pemphigoid: Diagnosis and Treatment , 1996, International ophthalmology clinics.
[19] C. Foster,et al. Systemic immunosuppressive therapy and the occurrence of malignancy in patients with ocular inflammatory disease. , 1995, Ophthalmology.
[20] O. Førre. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Norwegian Arthritis Study Group. , 1994, Arthritis and rheumatism.
[21] H. Thiel,et al. Zur Bedeutung der Autoimmunität bei verschiedenen Uveitisformen , 1991 .
[22] M. Zierhut,et al. [Significance of autoimmunity in various forms of uveitis]. , 1991, Klinische Monatsblätter für Augenheilkunde.
[23] P. Tugwell,et al. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis , 1990, The Lancet.
[24] L T Chylack,et al. Lens opacities classification system II (LOCS II) , 1989, Archives of ophthalmology.
[25] R. Nussenblatt,et al. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. , 1987, American journal of ophthalmology.
[26] R. Nussenblatt,et al. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. , 1985, Ophthalmology.
[27] A. Ahmed,et al. Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses. , 1984, Journal of the American Academy of Dermatology.